AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04554771 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin AUC = 2 will be given intravenously on days 1, 8, 15, 22 and 29
Study NCT04554771 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: External beam radiotherapy
Description: External beam radiotherapy will be delivered to a total dose of 41.4 Gy in 23 fractions of 1.8 Gy, 5 fractions per week starting the first day of the first cycle of chemotherapy
Study NCT04554771 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External beam radiotherapy
Description: External beam radiotherapy will be delivered to a total dose of 41.4 Gy in 23 fractions of 1.8 Gy, 5 fractions per week starting the first day of the first cycle of chemotherapy
Study NCT04866901 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Slow-Paced Breathing (SPB)
Description: see arm description
Study NCT04866901 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness (M)
Description: see arm description
Study NCT04866901 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yogic Breathing (SPB+M)
Description: see arm description
Study NCT04792411 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prehabilitation
Description: Multimodal, tailored prehabilitation programme
Study NCT05933707 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: People with Metabolically Unhealthy Obesity - Low Calorie Diet
Description: Consumption of a low-calorie diet with caloric intake reduced by \~25% to achieve \~10% weight loss in about 4 to 5 months.
Study NCT06183073 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: caudal block
Description: bupivacaine 0.25% in a dose of (1 ml / kg)
Study NCT06183073 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: dexmedetomidine 1μg/ kg.
Study NCT06183073 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TAP
Description: analgesia
Study NCT06183073 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacain
Description: bupivacaine 0.25% in a dose of (0.5 ml / kg
Study NCT04903327 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVI-MSC
Description: COVI-MSC are allogeneic culture-expanded adipose-derived mesenchymal stem cells
Study NCT04903327 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Excipient solution
Study NCT06092515 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fermented High Zinc Wheat Flour Flatbread
Description: * Participants in this group will receive flatbreads made from fermented high zinc wheat flour.~* The flatbreads will be prepared using traditional fermentation methods.~* These flatbreads will be provided to participants to consume daily, along with vegetables or pulses (daal), for six days a week over the course of six months.
Study NCT06092515 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Unfermented High Zinc Wheat Flour Flatbread
Description: * Participants in this group will receive flatbreads made from unfermented high zinc wheat flour,~* The flatbreads will not undergo a fermentation process.~* These flatbreads will be provided to participants to consume daily, along with vegetables or pulses (daal), for six days a week over the course of six months.
Study NCT06092515 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Post-Harvest Fortified Whole Wheat Flour Flatbread
Description: * Participants in this group will receive flatbreads made from whole wheat flour fortified post-harvest~* These fortified flatbreads will be provided to participants for daily consumption, along with vegetables or pulses (daal), for six days a week over the course of six months.
Study NCT06092515 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Low Zinc Whole Wheat Flour Flatbread (Control Group)
Description: * Participants in this group will serve as the control group.~* They will receive flatbreads made from whole wheat flour with a low zinc content~* These low zinc flatbreads will be provided to participants for daily consumption, along with vegetables or pulses (daal), for six days a week over the course of six months. six days a week over the course of six months.
Study NCT06616740 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Cricoid pressure
Description: Cricoid pressure will be applied during LMA ProSeal insertion.
Study NCT06616740 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Paratracheal pressure
Description: Pratracheal pressure will be applied during LMA ProSeal insertion.
Study NCT06661603 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: GSY Yoga Intervention
Description: In the GSY yoga intervention, where participants received 90 minutes/week yoga intervention for duration of 10 weeks.
Study NCT06676072 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PFA Ablation catheter
Description: Deliver RF and/or PF energy using the TactFlex PFA system
Study NCT05116787 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally twice daily
Study NCT05116787 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCX9930 monotherapy
Description: Administered orally twice daily
Study NCT05116787 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: BCX9930 monotherapy
Description: Administered orally twice daily
Study NCT06749327 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High UPF, high hPDI diet
Description: High ultra-processed foods (UPFs) and healthy plant based diet
Study NCT06749327 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Low UPF, high hPDI diet
Description: Low ultra-processed foods (UPFs) and high healthy plant-based diet
Study NCT06754735 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Topical Wound Oxygen Therapy
Description: The active intervention is the application of the Topical Wound Oxygen device that supplies cyclical oxygen pressure directly to the wound site within a sealed environment.
Study NCT06754735 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Control Topical Wound Oxygen
Description: The sham control intervention is the application of Topical Wound Oxygen device that supplies topical room air to the wound site within a sealed environment.
Study NCT06756321 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-CD19-CAR T-cells, or anti-CD30-CAR T-cells, or anti-CD20/CD30-CAR T-cells
Description: Each subject will be infused with single dose. A classic 3+3 dose escalation will be employed.~anti-CD19-CAR T-cells~Dose level 1：1x10\^5 CAR T cells/kg, Dose level 2：3x10\^5 CAR T cells/kg, Dose level 3：1x10\^6 CAR T cells/kg~anti-CD30-CAR T-cells~Dose level 1：3x10\^6 CAR T cells/kg, Dose level 2：6x10\^6 CAR T cells/kg, Dose level 3：1x10\^7 CAR T cells/kg~anti-CD20/CD30-CAR T-cells~Dose level 1：1x10\^6 CAR T cells/kg, Dose level 2：3x10\^6 CAR T cells/kg, Dose level 3：1x10\^7 CAR T cells/kg
Study NCT06756321 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine will be given at a dose of 25 mg/m\^2/day intravenously (IV) for 3 days prior to the infusion of CAR T-cells.
Study NCT06756321 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide will be given at a dose of 250 mg/m\^2/day intravenously (IV) for 3 days prior to the infusion of CAR T-cells.
Study NCT06756659 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Center-based exercise training
Description: All participants will undergo a spot jogging cardiopulmonary exercise test and a six-minute walking test. The outpatient center-based cardiac rehabilitation group will perform moderate-intensity stationary biking or treadmill exercise for 30 minutes, twice a week, under the supervision of a physical therapist in the outpatient cardiac rehabilitation room.
Study NCT06756659 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home-based spot jogging
Description: The home-based spot jogging cardiac rehabilitation group will receive exercise intensity guidance in the outpatient cardiac rehabilitation room for 30 minutes of spot jogging and treadmill exercise during the first, fourth, and seventh weeks. They will then perform moderate-intensity spot jogging at home for 30 minutes, twice a week, at a perceived exertion level of 13 out of 20 on the RPE scale.
Study NCT06758089 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lens 1 (ocufilcon D)
Description: 15 minutes of daily wear
Study NCT06758089 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lens 2 (somofilcon A)
Description: 15 minutes of daily wear
Study NCT06757062 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kinesiology Tape
Description: The kinesiology tape (KT) is applied with the dorsal application for the treatment of carpal tunnel syndrome (CTS). This method is utilized and explained in Krause et al. (2020). This study will assess the efficacy of the application method as well as the varying effects of the color of the KT. Red KT will be compared to skin tone KT. The skin tone KT will be color-matched as closely as possible to each participant's skin tone to reduce the effect of the KT color. In this way, the study's second purpose is to understand the potential effect of color on psychological function and performance in the context of aggressive first-person shooter esports games.
Study NCT05703087 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive cueing in the information video before a primary TKA
Description: Two weeks before the surgery, in the outpatient clinic (during their preoperative appointment), the pre-surgery information video was shown to the patients. Patients were randomly allocated to either the positive cueing group (intervention) or the standard care group (control) with Castor EDC (14) using a variable block randomization model. Patients did not know whether they watched the adapted video or the standard video.
Study NCT05622487 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Neural Therapy
Description: Neural therapy is a form of treatment that aims to act on the autonomic nervous system, by injecting local anesthetics into certain parts of the body.
Study NCT05622487 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Kinesio taping
Description: Kinesiotape is used for injury prevention, rehabilitation and performance enhancement. It has been shown to be clinically effective in increasing joint movements, increasing muscle activity, inducing muscle maximum torque earlier, and improving functional performance
Study NCT05314803 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga
Description: Participants receive the yoga program, which is delivered by a trained yoga instructor (completed at least a 200-hour yoga teacher training, Yoga Thrive Teacher Training Certification (or similar), and/or practical experience working with individuals affected by cancer). The first class of the week is comprised of 45 minutes of gentle, progressive, hatha-based yoga sequencing and postures with the last 15 minutes focused on guided behaviour change and mindfulness techniques that varies week-to-week, based on the participants in the class. The second class of the week is 60 minutes of gentle, yin-based yoga sequencing and postures with an element of opening and relaxing.
Study NCT05805891 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: bortezomib 2mg/week subcutaneous injection
Study NCT05671588 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Controlled combined exercise group
Description: Patients will undergo protocol-defined combined aerobic-resistant therapy on a cycling ergometer and multifunctional fitness device
Study NCT05671588 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional rehabilitation
Description: Patients will undergo conventional rehabilitation.
Study NCT04916795 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vupanorsen
Description: 80 mg subcutaneous injection
Study NCT06757062 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Kinesiology Tape
Description: The kinesiology tape (KT) is applied with the dorsal application for the treatment of carpal tunnel syndrome (CTS). This method is utilized and explained in Krause et al. (2020). This study will assess the efficacy of the application method as well as the varying effects of the color of the KT. Red KT will be compared to skin tone KT. The skin tone KT will be color-matched as closely as possible to each participant's skin tone to reduce the effect of the KT color. In this way, the study's second purpose is to understand the potential effect of color on psychological function and performance in the context of aggressive first-person shooter esports games.
Study NCT06756854 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Biologic Agent: injectable platelet rich fibrin.
Description: injection of I-PRF to thin gingival phenotype 3 times with 7 days interval between sessions.
Study NCT06756854 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: injecable platelet rich fibrin, and low level laser therapy radiation.
Description: injection of I-PRF+ exposure to LLLT to thin gingival phenotype 3 times with 7 days interval between sessions.
Study NCT06756815 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cross bracing and conservative treatment
Description: Week Exercise Training Frequency (sets x reps) Week 1-2 1. Cross Bracing (Isometric Holds) 2. Quad Sets 3. Straight Leg Raise 4. Ankle Pumps 5. Heel and Toe Raises 6. Glute Bridge 2 sets x 10 reps Week 3-4 1. Cross Bracing (Isometric Holds) 2. Hamstring Curls 3. Step-ups 4. Mini Squats (with support) 5. Leg Press 6. Lateral Leg Raises 3 sets x 12 reps Week 5-6 1. Cross Bracing (Isometric Holds) 2. Single-leg Balance (with support) 3. Lunges (with proper technique) 4. Squats (bodyweight) 5. Box Jumps 6. Lateral Step-ups 3 sets x 15 reps
Study NCT06756815 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cross bracing and DNS with conservative treatment
Description: Week Exercise Training Frequency (sets x reps) Week 1-2~1. Cross Bracing (Isometric Holds)~2. DNS Core Activation (supine, prone positions)~3. Quad Sets~4. Straight Leg Raise~5. Ankle Pumps~6. Heel and Toe Raises~7. Glute Bridge 2 sets x 10 reps Week 3-4~1. Cross Bracing (Isometric Holds) 2. DNS Core Stabilization (advanced activation) 3. Hamstring Curls 4. Step-ups 5. Mini Squats 6. Leg Press 7. Lateral Leg Raises 8. Pelvic Tilts 3 sets x 12 reps Week 5-6~1. Cross Bracing (Isometric Holds)~2. DNS Dynamic Stabilization (with resistance)~3. Single-leg Balance (with and without support)~4. Lunges (with added resistance)~5. Squats (bodyweight or weighted)~6. Box Jumps~7. Lateral Step-ups~8. Running Drills (if tolerated) 3 sets x 15 reps
Study NCT06758531 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Instant coffee given as a drink
Description: Commercially available instant coffee (3.6 g) will be provided in the form of a drink prepared with 400 ml of water. A standard breakfast consisting of cereal with milk will be provided at 60 mins after the intervention. A standard lunch (cheese sandwiches, potato crisps and shortbread biscuits) will be given at 300 after coffee intake.
Study NCT06758531 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Coffee given in a tablet form
Description: Commercially available instant coffee (3.6 g) will be provided as 4 tablets given with 400 ml of water. A standard breakfast consisting of cereal with milk will be provided at 60 mins after the intervention. A standard lunch (cheese sandwiches, potato crisps and shortbread biscuits) will be given at 300 after coffee intake.
Study NCT06758531 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control (placebo)
Description: A caffeine and coffee free control (3.6 g) will be provided as 4 tablets given with 400 ml of water. A standard breakfast consisting of cereal with milk will be provided at 60 mins after the intervention. A standard lunch (cheese sandwiches, potato crisps and shortbread biscuits) will be given at 300 after coffee intake.
Study NCT06756464 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ROHKEA: Virtual Reality Therapy
Description: Using Interpretative Phenomenological Analysis (IPA): an exploration of the therapeutic benefits of a Virtual Reality enhanced Cognitive Behavioural Therapy (CBT) and movement (graded exposure) therapy 60-day chronic pain management programme (CPMP). Using the ROHKAE device and undertaking semi structures interviews, pain questionnaires and patient diaries to measure patient experience and pain management
Study NCT06757621 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Regional Nodal Irradiation
Description: Patients will receive chest wall / breast radiation with or without regional nodal irradiation
Study NCT06758011 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ivWatch
Description: Patients wear ivWatch device at time of already scheduled chemotherapy on study.
Study NCT06757608 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Assessment of postprandial metabolism after intake of different meat
Description: 30 healthy adults (15 male and 15 female) consumed sardines (Opisthonema oglinum, marine fish), tambaqui (Colossoma macropomum, freshwater culture), and beef (Bos taurus). The meal consisted only of meat, with 7g per BMI unit. The postprandial response was observed for 5 hours, after an overnight fast.
Study NCT05963724 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Real-Time Computer Aided Detection
Description: This intervention involves using computer-aided detection using a real-time system (GI-Genius, Medtronic)
Study NCT05963724 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Stanford Colonoscopy
Description: This involves white-light colonoscopy
Study NCT06091124 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adebrelimab
Description: Adebrelimab 1200 mg IV on Day 1, once every 3 weeks for up to 4 cycles (each cycle = 21 days)
Study NCT06091124 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Etoposide 0.1g IV on Days 1-3, once every 3 weeks for up to 4 cycles (each cycle = 21 days)
Study NCT06091124 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin 35mg/m2 IV on Days 1-2, once every 3 weeks for up to 4 cycles (each cycle = 21 days)
Study NCT06091124 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical Cystectomy
Description: Radical cystectomy should be performed within 4-6 weeks after completion of last dose
Study NCT05579249 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: Participants will receive semaglutide 2.4 milligrams (mg) subcutaneous (s.c.) injection once weekly for 52 weeks.
Study NCT05579249 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Orlistat
Description: Participants will receive one of 4 commercially available anti-obesity medication chosen by the study doctor for 52 weeks. The 4 anti-obesity medications are orlistat per os \[by mouth\] (p.o.), phentermine/topiramate extended release p.o., naltrexone/bupropion extended release p.o. or liraglutide 3.0 mg s.c injection.
Study NCT05579249 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phentermine/Topiramate
Description: Participants will receive one of 4 commercially available anti-obesity medication chosen by the study doctor for 52 weeks. The 4 anti-obesity medications are orlistat per os \[by mouth\] (p.o.), phentermine/topiramate extended release p.o., naltrexone/bupropion extended release p.o. or liraglutide 3.0 mg s.c injection.
Study NCT05579249 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naltrexone/Bupropion
Description: Participants will receive one of 4 commercially available anti-obesity medication chosen by the study doctor for 52 weeks. The 4 anti-obesity medications are orlistat per os \[by mouth\] (p.o.), phentermine/topiramate extended release p.o., naltrexone/bupropion extended release p.o. or liraglutide 3.0 mg s.c injection.
Study NCT05579249 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liraglutide
Description: Participants will receive one of 4 commercially available anti-obesity medication chosen by the study doctor for 52 weeks. The 4 anti-obesity medications are orlistat per os \[by mouth\] (p.o.), phentermine/topiramate extended release p.o., naltrexone/bupropion extended release p.o. or liraglutide 3.0 mg s.c injection.
Study NCT06352775 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calcium Carbonate
Description: We will be using it in routes and doses consistent with its approved uses. Per the drug label information for Calcium Carbonate USP 500 mg found in the US National Library of Medicine, adults may take 2-4 tablets as symptoms occur and if pregnant to not exceed 10 tablets in 24 hours. Therefore, using a dosing of 500mg every 4 hours will be well below that guidance. When both cervical ripening has been completed and the oxytocin administration begins, the calcium carbonate treatment group will be given calcium carbonate 500mg every 4 hours (not to exceed 10 tablets in 24 hours) until they deliver.
Study NCT05693935 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TV-44749 - Dose level 1
Description: In Period 1, 2 monthly injections. In Period 2, up to 12 monthly injections
Study NCT05693935 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TV-44749 - Dose level 2
Description: In Period 1, 2 monthly injections, In Period 2 up to 12 monthly injections
Study NCT05693935 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TV-44749 - Dose level 3
Description: In Period 1, 2 monthly injections. In Period 2, up to 12 monthly injections